Загрузка...
Progress and challenges for treating Type 1 diabetes
It has been more than 30 years since the initial trials of Cyclosporin A to treat patients with new onset Type 1 diabetes (T1D). Since that time, there have been insights into genetic predisposition to the disease, the failures of immune tolerance, and mechanisms that cause the immune mediated β cel...
Сохранить в:
| Опубликовано в: : | J Autoimmun |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4903889/ https://ncbi.nlm.nih.gov/pubmed/27210268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaut.2016.04.004 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|